Among the types of HT, tamoxifen (TMX) is highlighted as a selective ER modulator recommended for premenopausal women(3), while aromatase inhibitors (AIs), such as exemestane, letrozole, and anastrozole (ANTZ), are used for postmenopausal women with breast cancer. Here, CYP19A1 is linked to breast carcinoma.